PDCD1 and neoplasm: Oncoviral tumor-localized delivery of this mAb may improve the therapeutic window for CTLA-4 targeted checkpoint intervention, allowing better tolerated and more effective combination therapy with approved antibodies targeting the PD-1/PDL1 axis.